- Do all PADs require a prior authorization (PA)?
- No – only the Healthcare Common Procedure Coding System (HCPCS) and PADs listed in Appendix Y require a prior authorization
- Please refer to the Physician Administered Drugs web page
- What is the maximum length for a PAD PA?
- PA approval length may be up to a maximum of 1 year (365 days)
- The maximum PA approval length specific for each HCPCS requiring a PA can be found on Appendix Y
- Are retro PA requests (PARs) allowed for PADs?
- Retro requests are currently not allowed in the CO PAD program with few exceptions due to extenuating circumstances prior to May 1, 2022
- Retro requests are currently not allowed in the CO PAD program with few exceptions due to extenuating circumstances prior to May 1, 2022
- What are the normal operating hours for Acentra?
- Normal operating hours for PAD clinical review is Monday through Friday from 7:00 am to 5:00 pm MST
- After hours coverage will be available for PA review as appropriate
- How do I submit a PAR?
- PARs may be submitted via Acentra
- Additional helpful links:
- Video recordings, training manuals, user guides, etc. can be found on the ColoradoPAR Training webpage
- Provider Portal User Guide
- Provider Contacts
- What kind of supporting documentation is required for PAR submission?
- Supporting documentation may consist of:
- Chart notes confirming the patient’s diagnosis
- Dosage and history of treatment with requested medication
- History of prior medications which have been tried and failed
- Additional information which may be requested as needed
- Supporting documentation may consist of:
- What are the turnaround times (TAT) for a PAD PA determination to be made?
- From the time a completed request is received (a request is complete upon submission of all pertinent information)
- PAD Prospective Standard Request: 24 hours TAT
- PAD Urgent (Expedited) Request (must meet the urgent request standards): 4 hours TAT
- All requested information submitted on the portal as a response to a request for more information (RFI): 24 hours TAT
- From the time a completed request is received (a request is complete upon submission of all pertinent information)
- What constitutes an Urgent (Expedited) Request?
- An expedited PAD PAR is that which is urgent (expedited) because a delay in treatment could:
- Jeopardize the life or limb of the member OR
- Jeopardize the member’s ability to attain, regain, and/or maintain maximum function
- An expedited PAD PAR is that which is urgent (expedited) because a delay in treatment could:
- Remicade is listed as requiring a PA – what about biosimilar drugs?
- Only the HCPCS and PADs listed on Appendix Y require a PA
- Only the HCPCS and PADs listed on Appendix Y require a PA
- What are the next steps after a PAR is denied?
- Following a PAR denial, there are three potential options which may be pursued:
- Reconsideration Request
- The provider may request a reconsideration to Acentra within ten (10) days of the initial denial
- Additional information and documentation must be submitted for reconsideration of the PAR
- Peer to Peer (P2P) Request
- The provider may request a Peer-to-Peer review within five (5) days from the date of the medical necessity adverse determination.
- A P2P cannot be performed on a technical or administrative denial.
- Formal Appeal
- Additional information will be provided in denial letters
- Process must be pursued by the member
- It is strongly encouraged that a provider exhaust both reconsideration and P2P options prior to a member pursuing a formal appeal.
- Reconsideration Request
- Following a PAR denial, there are three potential options which may be pursued:
- How often will Appendix Y be updated?
- Appendix Y may be updated on an as needed basis and usually in conjunction with determinations made during the review of PA criteria at quarterly Drug Utilization Review Board (DUR) meetings.
- Information related to the DUR Board, including meeting agendas can be found on the Drug Utilization Review Board web page.
- Appendix Y may be updated on an as needed basis and usually in conjunction with determinations made during the review of PA criteria at quarterly Drug Utilization Review Board (DUR) meetings.